News

Per capita state suicide prevention funding rose 6-fold from 2021 to 2025 and was more than double in states with 988 telecom fees, study finds.

Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.

New NIH-funded study probes why many callers avoid returning to 988, linking user experiences and state systems to improve crisis support nationwide.

Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.

How postmodern ideas shape DSM and the biopsychosocial model—why psychiatry needs method-based, truth-seeking care beyond consensus and eclecticism.

Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.

Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.

Learn why SSRIs impair sex and how bupropion, PDE5 inhibitors, buspirone, and newer agents can prevent or reverse antidepressant sexual side effects.

Catch up on psychiatry news from last week.

FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.

Experts unpack screening for sexual dysfunction in psychiatric care, menopause and meds impacts, and when flibanserin may help restore desire.

Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change.

Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.

Review the developments in GLP-1s in 2026.

A target trial emulation of more than 1.5 million matched adults ties GLP-1 RA initiation to lower mortality and cardiovascular events in serious mental illness.

New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.

ACP outlines ethical AI use in medicine—protect patient trust, curb bias, prevent deskilling, and guide transparent, equitable care.

Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.

International Overdose Awareness Day marks 25 years, spotlighting fragile declines in deaths and urging naloxone access, harm reduction funding, and stigma-free care.

Much of what we call "treatment-resistant" depression may be mismatched, not resistant. A psychiatrist makes the case for trading the failed-drug tally for a difficult-to-treat framework clinicians can act on Monday morning.

BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.

Check out our pipeline updates from August!

Axsome launches SUMMIT phase 3 testing AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

Neurobiology of antisocial behavior links prenatal stress, childhood trauma, toxins, and brain-circuit deficits to proactive vs reactive aggression and psychopathy.

Review news in psychiatry from the last week.

Livestreamed insanity trials reshape public opinion, exposing myths, bias, and psychiatry’s educator role, in cases like the M’Naghten trial to the curent Clancy trial.

Drs Clark and Walton discuss ADHD in underrecognized groups, along with treatment and lifestyle options.

Meta faces an $18B teen-safety settlement, adding time limits, night and school modes, parental controls, and tighter age checks across Instagram and Facebook.

New donanemab dosing cuts ARIA-E risk, speeds MRI monitoring, and shows durable 3-year benefits with lasting biomarker gains in early Alzheimer’s.

Recap Alzheimer disease updates from August.